Organisation paid for research Program year 2022 Source: CMS Open Payments

Millennium Psychiatric Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$971,524

97 payments

Through program year 2022, Millennium Psychiatric Associates LLC is reported as receiving $971,524 in research payments, across 97 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $2,877 1
2021 Research $69,739 5
2020 Research $400,684 45
2019 Research $498,224 46

Breakdown

Who paid Research payments · program years 2019–2022
  1. Teva Pharmaceuticals USA, Inc. $398,225 52 payments
  2. Genentech, Inc. $286,352 36 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $116,029 2 payments
  4. Eli Lilly and Company $85,162 2 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $59,925 2 payments
  6. F. Hoffmann-La Roche AG $25,076 1 payment
  7. ACADIA Pharmaceuticals Inc $756 2 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $372,578 42 payments
  2. Phase III Study of Balovaptan in Adults With Asd $251,693 28 payments
  3. PoCC dose finding in Mild to Moderate AD $116,029 2 payments
  4. A 24-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of Azd3293 in Early Alzheimers Disease -The Amaranth Study $84,074 1 payment
  5. Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $51,768 1 payment
  6. Gantenerumab Mild Ad $32,969 7 payments
  7. A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $25,646 10 payments
  8. PH Ib Crenezumab Eff Sfy Mild Mod Ad $25,076 1 payment
  9. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $8,157 1 payment
  10. Prodromal to Mild Ad $1,690 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record